Drug combo aims to shrink NF2 tumors and save hearing
NCT ID NCT07708285
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This trial tests whether combining two drugs—luvometinib (a targeted therapy) and serplulimab (an immunotherapy)—can shrink tumors and improve hearing in people with NF2-related schwannomatosis. Participants have progressive vestibular schwannomas or meningiomas that are not suitable for surgery. The study measures tumor response and hearing improvement, while monitoring safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two drugs: luvometinib (a MEK inhibitor taken orally) and serplulimab (an immunotherapy given by IV infusion)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with NF2-related tumors that are not suitable for surgery, potentially preserving hearing and reducing tumor burden.
- What could go wrong
- This is an early-phase, small study (30 participants) with no control group, so results may not apply broadly. The combination may cause side effects from both drugs, and it is not yet known if it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
Changchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Radiation's hidden toll on the brain: new study maps cognitive changes to protect patients
- New combo aims to stall aggressive brain tumors when surgery and radiation fail
- New MRI dye could spot aggressive brain tumors without surgery